Obviously the Directors have opted to take the cash and promises of cushy highly paid positions plus any accrued entitlements from Cellestis and opted to shaft their patient shareholders.
Remember the Company has grown during some very tough times (GFC, tighter healthcare funding and now high Aussie dollar). Better times could certainly be expected over the next few years, so to base the offer on a moddest premium on what was a depressed share price/market capitalisation is totally opportunistic.
For me this investment was to be a growth stock with handy dividends well into the future supporting retirement. Although the current offer price gives me potential for a reasonable capital gain it barely covers "opportunity losses" if I look at it from that angle.
I would be confident a majority of shareholders would feel the same way and enough be prepared to block this current offer. I have seen the momentum bulding on SS already and added my total holdings to the list (different ID on SS).
CST Price at posting:
$3.47 Sentiment: Hold Disclosure: Held
